These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 17091285)
1. [Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study]. Lordick F; Siewert JR Chirurg; 2006 Dec; 77(12):1166-7. PubMed ID: 17091285 [No Abstract] [Full Text] [Related]
2. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Briasoulis E; Fatouros M; Roukos DH Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806 [No Abstract] [Full Text] [Related]
3. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Chua YJ; Cunningham D Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804 [No Abstract] [Full Text] [Related]
4. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ BMC Surg; 2015 May; 15():66. PubMed ID: 25997454 [TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Ychou M; Boige V; Pignon JP; Conroy T; Bouché O; Lebreton G; Ducourtieux M; Bedenne L; Fabre JM; Saint-Aubert B; Genève J; Lasser P; Rougier P J Clin Oncol; 2011 May; 29(13):1715-21. PubMed ID: 21444866 [TBL] [Abstract][Full Text] [Related]
6. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer. Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520 [TBL] [Abstract][Full Text] [Related]
7. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors. Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777 [TBL] [Abstract][Full Text] [Related]
8. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852 [TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992 [TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma. van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156 [TBL] [Abstract][Full Text] [Related]
13. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Melcher AA; Mort D; Maughan TS Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350 [TBL] [Abstract][Full Text] [Related]
14. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890 [TBL] [Abstract][Full Text] [Related]
15. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience. Strickland AH; Karapetis CS; Yip D; Harper PG Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143 [No Abstract] [Full Text] [Related]
17. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411 [TBL] [Abstract][Full Text] [Related]